9. Humulin

Humulin's sales growth measured a substantial 13% in the U.S.

Company: Eli Lilly
2016 U.S. sales: $862 million
Drug class: Human insulin

Eli Lilly’s Humulin has been around for a long, long time, but it’s still pumping out sales growth. In 2016, that sales growth measured a substantial 13% in the U.S.

The reasons? Demand for the Indianapolis drugmaker’s product increased, it said, and that was the primary driver. But Lilly also benefitted from higher net prices, thanks to a change in the estimate of a government rebate in the first quarter of last year.

For a long time, Lilly kept the growth coming with list price increases on its elderly and long-off-patent med. Between 2007 and 2013, Humulin’s price leapt by 354%, offsetting payer pressure and the termination of an agreement with Walmart.

After taking a 17.5% price hike on Humulin in 2015, however, Lilly cut its increase by more than half to 7.5% in 2016, according to Wells Fargo analyst David Maris. And as of late January of this year, the company had yet to take one at all.

9. Humulin

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.